For the quarter ending 2025-09-30, XERS made $143,187,000 in revenue. $620,000 in net income. Net profit margin of 0.43%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Unrealized gains (losses) on investments | 0 | 0 | - | - |
| Other comprehensive income (loss), foreign currency transaction and translation gain (loss) arising during period, net of tax | -1,000 | 1,000 | - | - |
| Cost of goods sold | 10,996,000 | 11,898,000 | 8,728,000 | 7,724,500 |
| Research and development | 7,483,000 | 8,055,000 | 7,753,000 | 6,956,500 |
| Selling, general and administrative | 46,459,000 | 44,393,000 | 44,018,000 | 39,259,500 |
| Amortization of intangible assets | 2,711,000 | 2,711,000 | 2,710,000 | 2,711,000 |
| Total costs and expenses | 67,649,000 | 67,057,000 | 63,209,000 | 56,651,500 |
| Product revenue, net | 74,380,000 | 71,539,000 | 60,119,000 | 50,368,500 |
| Income (loss) from operations | 6,731,000 | 4,482,000 | -3,090,000 | -6,283,000 |
| Interest and other income | 1,158,000 | 948,000 | 1,175,000 | 1,416,500 |
| Debt refinancing costs | 0 | 0 | - | 672,500 |
| Interest expense | 7,268,000 | 7,358,000 | 7,305,000 | 6,695,833.333 |
| Change in fair value of warrants | 0 | 0 | - | -1,666.667 |
| Change in fair value of contingent value rights | 0 | 0 | - | -1,683,500 |
| Total other expense | -6,110,000 | -6,410,000 | -6,130,000 | -5,610,000 |
| Net income (loss) before income taxes | 621,000 | -1,928,000 | -9,220,000 | -11,893,000 |
| Income tax benefit | 0 | 0 | - | 153,500 |
| Net income (loss) | 621,000 | -1,928,000 | -9,220,000 | -12,046,500 |
| Comprehensive income (loss) | 620,000 | -1,927,000 | -9,220,000 | -12,057,000 |
| Net loss per common share - basic (in dollars per share) | 0 | -0.01 | -0.06 | -0.08 |
| Net loss per common share - diluted (in dollars per share) | 0 | -0.01 | -0.06 | -0.08 |
| Weighted average common shares outstanding - basic (in shares) | 163,649,932 | 159,459,413 | 152,445,935 | -75,283,307 |
| Weighted average common shares outstanding - diluted (in shares) | 177,617,307 | 159,459,413 | 152,445,935 | -75,283,307 |
Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS)